Showing 1711-1720 of 2224 results for "".
- New Collaboration Enhances Precision and Patient Engagement in Post-Weight-Loss Treatmentshttps://modernaesthetics.com/news/new-collaboration-enhances-precision-and-patient-engagement-in-post-weight-loss-treatments/2475376/MNML Aesthetics announced a partnership with ShapeScale to integrate 3D body imaging into its MNML Tone Method, a multi-modality body contouring protocol. The collaboration aims to enhance clinical precision and patient engagement in aesthetic practices, particularly in post-weight-loss body tran
- Analysis: PBoNT/A and ABoNT/A Show Fastest Onset in Glabellar Line Treatmenthttps://modernaesthetics.com/news/analysis-pbonta-and-abonta-show-fastest-onset-in-glabellar-line-treatment/2475374/A newly published study reports the comparative effects of four botulinum toxin A (BoNT/A) formulations on glabellar strain, with observed differences in onset, longevity, and muscular strain patterns. Researchers pu
- Zenoti President Elaborates on Data About Membership Programshttps://modernaesthetics.com/news/zenoti-president-elaborates-on-data-about-membership-programs/2475373/Businesses that prioritized memberships saw their revenue grow 5% year-over-year in 2024, more than double the industry average, according to new data released by spa software provider Zenoti. The company said membership sales for spas and salons increased by 24%, while average ticket si
- Revance Announces CEO Transitionhttps://modernaesthetics.com/news/revance-announces-ceo-transition/2475370/Revance announced a leadership transition last week as part of a long-term succession strategy following its integration with Crown Laboratories, according to a news release from the company. Founder and CEO of Crown Laboratories Jeff Bedard will assume the role of Executive Chai
- First Patient Dosed with GPX4 Modulator Targeting Pathologic Senescent Cellshttps://modernaesthetics.com/news/first-patient-dosed-with-gpx4-modulator-targeting-pathologic-senescent-cells/2475369/The first patient has been dosed with the lead drug candidate RLS-1496 in a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial, Rubedo Life Sciences, Inc., announced in a press release. The study marks the first time a glutathio
- New Artificial Intelligence Platform to Enhance Leads, Conversions, and Retention for Private-Pay Clinicshttps://modernaesthetics.com/news/new-artificial-intelligence-platform-to-enhance-leads-conversions-and-retention-for-private-pay-clinics/2475367/BoomerangFX announced the global launch of LeadEngineAITM, an AI-powered platform designed to streamline and automate lead generation and conversion for private-pay healthcare clinics. A press release from the manufacturer said that the tool integrates marketing automation, CR
- ASLMS 2025: E. Victor Ross, MD, Talks Landscape of Fractional Laser Treatmentshttps://modernaesthetics.com/news/aslms-2025-e-victor-ross-md-talks-landscape-of-fractional-laser-treatments/2475359/At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, E. Victor Ross, MD, shared insights on the evolving role of fractional lasers in dermatologic practice, highlighting both their advantages and limitations. Risk, Recovery, and Pigmentatio
- ASLMS 2025: New Laser Platforms Expand Options for Vascular Rosaceahttps://modernaesthetics.com/news/aslms-2025-new-laser-platforms-expand-options-for-vascular-rosacea/2475358/Advanced vascular lasers are transforming the treatment of rosacea by targeting its root cause (chronic vascular dilation) rather than just managing inflammation. At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, Eric Bernstein, MD, Director of
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://modernaesthetics.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2475357/Key Takeaways Individuals aged 18–39 make up two-thirds of those seeking tattoo removal, with visible areas such as forearms and hands being the most treated. Black ink remains the most commonly removed tattoo pigment. Fitzpatrick Skin Types III and
- Men’s Aesthetic Practice Announces New Chief Medical Director for San Diego Clinichttps://modernaesthetics.com/news/mens-aesthetic-practice-announces-new-chief-medical-director-for-san-diego-clinic/2475355/Lushful Aesthetics, a leader in specialized sexual health and enhancement procedures, named Dr. Carlton Thomas as chief medical director of its new clinic in San Diego. Dr. Thomas will oversee medical operations next to Lushful Aesthetics founder Chris Bustamante, DNP, NP-C. Dr. Thomas gai